I applaud the Sept. 16 article CDC calls for action on drug-resistant bacteria, describing how the lack of new antibiotics is limiting doctors’ ability to battle drug-resistant bacteria. It was correctly noted that much more action is needed on the antibiotic front. But more broadly, we should seek to build an “all of the above” antibacterial arsenal that includes more than just antibiotics.
One of the most promising of these potential weapons is “phage therapy” — enlisting bacteria’s most significant natural enemies, predatory viruses, bacteriophages, on our behalf. Unfortunately, the FDA’s current regulatory framework is impeding research and commercialization of phage therapy. To meet the critical challenge of multidrug-resistant bacteria, we should be creating streamlined regulatory pathways for all promising antibacterial treatments, not just antibiotics.
Eric Keen, Coral Gables